How do I manage nocardiosis?

Area of Science:

• Infectious Diseases
• Microbiology
• Clinical Medicine

Background:

• Nocardiosis is a rare, opportunistic infection, often affecting the lungs and potentially disseminating to the central nervous system.
• It can occur in both immunocompetent and immunocompromised individuals, posing significant treatment challenges due to a lack of management consensus.
• Accurate Nocardia species identification via molecular methods and antibiotic susceptibility testing (AST) are crucial but often delayed.

Purpose of the Study:

• To systematically review current evidence for diagnosing and managing nocardiosis.
• To propose a practical management approach for this uncommon infection.
• To provide clinicians with an evidence-based algorithm for patient care.

Main Methods:

• Systematic literature search of medical publications on nocardiosis.
• Studies included were published between 2010 and 2020.
• Focus on studies describing ten or more individuals to ensure sufficient data.

Main Results:

• Trimethoprim-sulfamethoxazole is the preferred initial antibiotic therapy due to high susceptibility rates.
• Linezolid serves as a viable alternative, with combination therapies including third-generation cephalosporins, amikacin, or imipenem for severe cases.
• Treatment duration typically spans 6 months, adjusted for disease severity and patient factors; secondary prophylaxis may be considered.

Conclusions:

• An easy-to-use management algorithm for nocardiosis is presented to guide clinicians.
• The review highlights existing evidence gaps in nocardiosis diagnosis and treatment.
• Future research directions are suggested to improve patient outcomes and management strategies.